News
TABLE-Early Age - 6-MTH group results
1+ hour, 36+ min ago (19+ words) Trading View TABLE-Early Age - 6-MTH group results More news from Reuters...
RAPP: Global phase III epilepsy trials advance with robust data and broad commercial potential
2+ day, 13+ hour ago (81+ words) Trading View Phase III trials for RAP-219 in focal-onset seizures are enrolling globally, supported by strong phase II data and a China partnership to accelerate recruitment. The pipeline includes upcoming trials in bipolar mania, primary generalized tonic-clonic seizures, and pain,…...
Fewer Chinese teenagers register for tough university entry exam
6+ day, 1+ hour ago (23+ words) Trading View Fewer Chinese teenagers register for tough university entry exam More news from Reuters...
RAPP: RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing
1+ week, 16+ hour ago (78+ words) Trading View RAP-219, a precision neuroscience asset, is advancing through phase III trials for focal epilepsy, with strong phase II efficacy and a robust safety focus. A long-acting injectable is in development, and pivotal data for bipolar mania and open…...
Solana Summer School to Start on June 15
2+ week, 19+ hour ago (87+ words) Trading View Solana Summer School to Start on June 15 Solana Foundation announced that Solana Summer School will begin on June 15 as a virtual program for current college students. According to the Luma page, the program includes five weeks of live…...
Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7. 2/7. 3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
2+ week, 1+ day ago (51+ words) Trading View Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7. 2/7. 3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile More news from Reuters...
Berachain (BERA) - Po L Next on Bepolia - Date (26 May 2026)
2+ week, 6+ day ago (131+ words) Trading View Berachain (BERA) - Po L Next on Bepolia - Date (26 May 2026) According to the Berachain team's announcement on X, the Po L Next upgrade is going live on the Bepolia testnet, phasing out BGT/boost mechanics and redirecting emissions and…...
Bio Marin's drug shows significant growth gains in children in late-stage trial
3+ week, 9+ hour ago (29+ words) Trading View Bio Marin's drug shows significant growth gains in children in late-stage trial More news from Reuters...
DBV: Skin-based immunotherapy for peanut allergy nears FDA filing, with pipeline and market expansion ahead
3+ week, 1+ day ago (82+ words) Trading View A novel skin-based immunotherapy for pediatric peanut allergy is nearing BLA filing, with a clear regulatory path and plans for pipeline expansion into other food allergies. Market entry will focus on allergists and parental engagement, with future growth…...
Shanghai exchange to adjust daily price limit and margin ratios for some steel futures contracts
3+ week, 5+ day ago (35+ words) Trading View Shanghai exchange to adjust daily price limit and margin ratios for some steel futures contracts More news from Reuters...